Eccogene (Shanghai) Co., Ltd
http://www.eccogene.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eccogene (Shanghai) Co., Ltd
AstraZeneca’s Hot Streak Whets Investor Appetite For What’s Next
Outstanding Q1 growth in sales and profits have pleased the markets, and investors are now keen to hear more about AstraZeneca’s 2030 masterplan at its investor day next month.
AstraZeneca Outlines Growth Ambitions – Could This Include Oncology Leadership By 2030?
Not content with fulfilling its decade-long $45bn sales target, AstraZeneca is now preparing for Act 2: a new 10-year 'cycle of growth'.
VBP Pains Swell Prompting New China Strategy, Local Innovation Focus
As the rollout of volume-based procurement to more products brings more pain, drug makers are exploring different China strategies. One indicator, though, is clear - local innovation and distribution can’t be ignored anymore.
Stock Watch: The Deal Flow Before Christmas
A bumper December of licensing transactions and acquisitions involving biotech companies brought the feelgood factor back to the sector. But while big spending in the run-up to Christmas may not dent pharma’s credit cards, it might crimp its investors’ dividends.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice